Stay updated on MK-3475 Combo vs Docetaxel Alone in NSCLC Clinical Trial
Sign up to get notified when there's something new on the MK-3475 Combo vs Docetaxel Alone in NSCLC Clinical Trial page.

Latest updates to the MK-3475 Combo vs Docetaxel Alone in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov footer now displays release version v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoChange DetectedThe clinical-trial record is displayed instead of an error page, with details about the pembrolizumab-plus-docetaxel versus docetaxel study, its participants and design, and its results. The record also includes study documents and information about sharing participant data.SummaryDifference56%

- Check15 days agoChange DetectedThe ClinicalTrials.gov record is now displayed for the completed phase II study comparing pembrolizumab (MK-3475) plus docetaxel with docetaxel alone in previously treated non-small cell lung cancer. It includes study details, outcome measures, participant criteria, and results-related information.SummaryDifference56%

- Check29 days agoChange DetectedA general NIH notice about changes in terminology appears above the 403 error page, and the site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedRevision: v3.7.0 was added to the page, signaling a site version update. A substantial set of older study documents and related entries were removed from the listing.SummaryDifference19%

Stay in the know with updates to MK-3475 Combo vs Docetaxel Alone in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-3475 Combo vs Docetaxel Alone in NSCLC Clinical Trial page.